GlassScriptPhysician profile
Sima Kalika
NPI 1982786240
$6,937.29
in general payments reported to CMS, 2019-2025
20 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,772 · 2020: $1,080 · 2021: $878 · 2022: $1,297 · 2023: $818 · 2024: $665 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,910.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,360.57 | 2019-2025 | Trulance, Xifaxan |
| Abbvie INC. | $1,388.68 | 2019-2025 | |
| Amgen INC. | $573.20 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $332.92 | 2019-2024 | Airsupra |
| Endo Pharmaceuticals INC. | $302.75 | 2019-2022 | |
| Amarin Pharma, INC. | $301.86 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $282.61 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $265.94 | 2021-2023 | |
| Lilly USA, LLC | $224.14 | 2022-2024 | Mounjaro, Zepbound |
| Optinose US, INC. | $170.73 | 2019 | |
| Merck Sharp & Dohme LLC | $158.28 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.65 | 2019-2021 | |
| Allergan, INC. | $83.83 | 2019-2020 | |
| Astellas Pharma US INC | $82.65 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $65.00 | 2022 | |
| Novo Nordisk INC | $42.80 | 2025 | Ozempic |
| Teva Pharmaceuticals USA, INC. | $28.98 | 2020 | |
| Vivus LLC | $23.71 | 2022 | |
| Sumitomo Pharma America, INC. | $14.99 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sima Kalika listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.